255 related articles for article (PubMed ID: 23146959)
1. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
Lee HE; Park KU; Yoo SB; Nam SK; Park DJ; Kim HH; Lee HS
Eur J Cancer; 2013 Apr; 49(6):1448-57. PubMed ID: 23146959
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.
Yang J; Luo H; Li Y; Li J; Cai Z; Su X; Dai D; Du W; Chen T; Chen M
Cell Biochem Biophys; 2012 Jan; 62(1):221-8. PubMed ID: 21927816
[TBL] [Abstract][Full Text] [Related]
3. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
4. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
5. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
[TBL] [Abstract][Full Text] [Related]
7. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
[TBL] [Abstract][Full Text] [Related]
8. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer.
Ahn S; Hong M; Van Vrancken M; Lyou YJ; Kim ST; Park SH; Kang WK; Park YS; Jung SH; Woo M; Lee J; Kim KM
Mol Diagn Ther; 2016 Aug; 20(4):375-83. PubMed ID: 27179810
[TBL] [Abstract][Full Text] [Related]
9. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
[TBL] [Abstract][Full Text] [Related]
10. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
11. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
[TBL] [Abstract][Full Text] [Related]
12. Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients.
Sornmayura P; Rerkamnuaychoke B; Jinawath A; Euanorasetr C
J Med Assoc Thai; 2012 Jan; 95(1):88-95. PubMed ID: 22379747
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
[TBL] [Abstract][Full Text] [Related]
14. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.
Sheffield BS; Garratt J; Kalloger SE; Li-Chang HH; Torlakovic EE; Gilks CB; Schaeffer DF
Arch Pathol Lab Med; 2014 Nov; 138(11):1495-502. PubMed ID: 25357111
[TBL] [Abstract][Full Text] [Related]
15. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.
Saito T; Kondo C; Shitara K; Ito Y; Saito N; Ikehara Y; Yatabe Y; Yamamichi K; Tanaka H; Nakanishi H
Pathol Int; 2015 Jun; 65(6):309-17. PubMed ID: 25828363
[TBL] [Abstract][Full Text] [Related]
17. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
[TBL] [Abstract][Full Text] [Related]
18. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
[TBL] [Abstract][Full Text] [Related]
19. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
Cappellesso R; Fassan M; Hanspeter E; Bornschein J; d'Amore ES; Cuorvo LV; Mazzoleni G; Barbareschi M; Pizzi M; Guzzardo V; Malfertheiner P; Micev M; Guido M; Giacomelli L; Tsukanov VV; Zagonel V; Nitti D; Rugge M
Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
[TBL] [Abstract][Full Text] [Related]
20. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S
Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]